Painful sex after menopause can come from tissue changes. It can also come from infection, pelvic pain, skin disease, medications, or trauma.
Ospemifene belongs in the genitourinary syndrome of menopause conversation only after that diagnosis work starts.
DailyMed labels OSPHENA as an oral tablet for moderate to severe painful sex and vaginal dryness due to menopause. [1]
Ospemifene is not a local vaginal product
Ospemifene is a selective estrogen receptor modulator. It is taken by mouth. That makes the safety review different from a local vaginal product.
Menopause Society guidance for genitourinary syndrome of menopause lists ospemifene among prescription options for bothersome genitourinary syndrome of menopause symptoms. [2]
The practical point is simple. A reader should not treat every genitourinary syndrome of menopause treatment as the same. Lubricants, moisturizers, vaginal estrogen, prasterone, ospemifene, pelvic-floor care, and infection care solve different problems.
The evidence is for vaginal and urinary symptoms
A pivotal phase 3 study reported that ospemifene improved vaginal tissue findings and symptoms in postmenopausal women. [3]
Another phase 3 trial studied moderate to severe vaginal dryness after menopause. [4]
Those studies support a genitourinary syndrome of menopause discussion. They do not establish ospemifene treats hot flashes, fatigue, weight gain, mood, or libido.
The red flags come before the prescription
Unexplained bleeding after menopause should not be self-treated. New pelvic pain, discharge, odor, fever, sores, or deep pain also needs medical review.
Because ospemifene is oral and systemic, a clinician should review clot history, stroke risk, cancer history, liver history, drug interactions, and whether hot flashes could worsen.
That safety review is not a formality. It is the reason to keep ospemifene pages in the clinician-led category.
Who this fits
Ospemifene may fit a postmenopausal woman whose main problem is moderate to severe painful sex or vaginal dryness from genitourinary syndrome of menopause, especially when she wants an oral prescription option and understands that it is systemic. It is less likely to fit when symptoms are mild, when local moisturizers or vaginal options have not been tried, or when the symptom is mainly low desire rather than pain.
It should be avoided as a self-directed shortcut when bleeding is unexplained, pelvic pain is new, infection is possible, or clot, stroke, liver, or cancer history needs specialist-level review first. The conversion-worthy promise is not "take this pill." It is diagnosis-first selection among several genitourinary syndrome of menopause treatments.
The visit should also separate pain with entry, deep pelvic pain, tearing, burning, recurrent urinary symptoms, skin irritation, and low desire. Those can overlap, but they do not all point to the same prescription or same specialist referral.
Decision table: when ospemifene may or may not fit
| Factor | Why it changes the plan |
|---|---|
| Moderate to severe painful sex or dryness from genitourinary syndrome of menopause | Ospemifene is labeled for these menopause-related symptoms. |
| Mild dryness only | Lubricants or moisturizers may be enough before systemic therapy. |
| Unexplained postmenopausal bleeding | Bleeding needs evaluation before treatment. |
| Clot, stroke, estrogen-sensitive cancer, or liver concerns | Systemic safety review becomes central. |
| Main complaint is low desire, fatigue, or hot flashes | Ospemifene is not the direct treatment target. |
Decision checkpoint: what changes the plan
| Signal | Why it changes the plan | What to do next |
|---|---|---|
| Painful sex, dryness, burning, urinary symptoms, or recurrent UTI-like symptoms dominate | This points toward genitourinary syndrome of menopause evaluation, not a generic hormone conversation. | Separate moisturizers, lubricants, vaginal estrogen, prasterone, ospemifene, pelvic-floor care, and infection testing. |
| Abnormal postmenopausal bleeding is present | Bleeding after menopause should not be explained away by dryness or treatment choice. | Get evaluated before starting or continuing a genitourinary syndrome of menopause prescription. |
| Clot, stroke, cancer, liver, breast-risk, or medication history is relevant | Route and systemic exposure change safety review. | Compare local and oral options against the patient's history. |
| The main complaint is low desire rather than pain or dryness | genitourinary syndrome of menopause therapy may not be the right target. | Ask whether hypoactive sexual desire disorder, genitourinary syndrome of menopause, pain, mood, relationship, medication, or pelvic-floor factors are driving symptoms. |
| Symptoms are mild and nonprescription measures have not been tried | Prescription escalation may not be the first move. | Start with diagnosis, lubricants or moisturizers when appropriate, and follow-up criteria. |
Evidence boundary
Genitourinary syndrome of menopause pages should be practical because the symptom is practical: sex hurts, dryness burns, or urinary symptoms recur. Menopause Society genitourinary syndrome of menopause guidance separates mild symptoms that may respond to nonprescription therapy from moderate to severe symptoms where vaginal estrogen, vaginal dehydroepiandrosterone, systemic estrogen, or ospemifene may be considered depending on safety and preference. [2]
The route matters. Ospemifene is oral and systemic; prasterone is a vaginal insert; vaginal estrogen is local low-dose therapy. Labels and guidance do not make these interchangeable. They create a comparison framework: symptom target, route, contraindications, bleeding evaluation, breast or clot history, patient preference, and follow-up. [1] [5]
The safety frame also protects against the wrong referral path. Genitourinary syndrome of menopause treatment is not a libido treatment by default, not systemic hormone replacement therapy for hot flashes by default, and not a reason to ignore bleeding, pelvic pain, infection symptoms, or skin disease.
What this changes at the visit
Bring the symptom pattern, severity, bleeding history, infection history, urinary symptoms, pain location, pelvic-floor symptoms, breast or clot history, cancer history, current hormones, and prior moisturizer or lubricant use. That lets the clinician compare local care, oral options, pelvic-floor therapy, infection testing, and safety limits.
What to ask a clinician
Ask:
- Is my pain or dryness clearly genitourinary syndrome of menopause, or should infection, pelvic-floor pain, skin disease, or trauma be evaluated first?
- Would lubricant, moisturizer, vaginal estrogen, prasterone, ospemifene, pelvic-floor therapy, or another plan fit best?
- Do my bleeding history, clot or stroke risk, cancer history, liver history, or medications make ospemifene a poor fit?
- How soon should symptoms improve if it is working?
- What bleeding, pelvic pain, discharge, or systemic symptoms should make me stop and call?
Bottom line
Ospemifene is a useful topic because women search for painful sex, dryness, and alternatives to vaginal estrogen after menopause.
The safe answer is narrow: ospemifene can be discussed for genitourinary syndrome of menopause-related painful sex and dryness in selected postmenopausal women. It is not local vaginal estrogen, not prasterone, not systemic hormone replacement therapy for hot flashes, and not a libido treatment. Diagnosis and safety review come first.
How the assessment helps
A clinical intake can use this as a triage signal around ospemifene safety, not a self-diagnosis shortcut. The assessment helps organize symptoms, uterus status, bleeding pattern, contraindication clues, medications, preferences, and treatment fit so a clinician can decide what belongs in the plan.
Systematic-review evidence supports ospemifene for dyspareunia from postmenopausal vulvovaginal atrophy, but that efficacy signal still has to be read alongside the product label, contraindications, and bleeding or clot-risk review. [6]
Related reading:
- Oxybutynin for Hot Flashes After Menopause.
- Perimenopause Bleeding Changes.
- Perimenopause Supplements.
References
[1] DailyMed. OSPHENA ospemifene tablet prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9accbcc9-78ee-4f84-9b7e-704f2ab1c413
[2] The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi:10.1097/gme.0000000000001609 https://pubmed.ncbi.nlm.nih.gov/32852449/
[3] Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480-6. doi:10.1097/gme.0b013e3181c1ac01 https://pubmed.ncbi.nlm.nih.gov/20032798/
[4] Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause. 2019;26(6):611-621. doi:10.1097/gme.0000000000001292 https://pubmed.ncbi.nlm.nih.gov/30694917/
[5] DailyMed. INTRAROSA prasterone vaginal insert prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df731acd-7276-4fef-b037-bc7f30c112cb
[6] Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014;11(2):487-97. doi:10.1111/jsm.12377 https://pubmed.ncbi.nlm.nih.gov/24251418/